GenDxTec Targets Animal Disease Molecular Diagnostics Blue Ocean with Partnerships Across 500+ Pet Hospitals

The pet healthcare sector is experiencing a significant boom, and as a critical component of this industry, in vitro diagnostics for pets holds immense development potential.

Current pet diagnostic testing is largely focused on complete blood count (CBC), biochemistry panels, and infectious disease screening. The first two categories constitute routine testing, while the latter involves targeted clinical diagnostics performed in response to overt clinical signs of disease in pets.

Common diagnostic methods on the market employ colloidal gold assays (test strips), which are primarily used for the detection of viral proteins. However, due to the approximately one-week window period associated with antibody-antigen testing, detection is only possible when pets exhibit clinical symptoms, i.e., during the middle to late stages of disease progression. By this time, the disease has already caused certain harm to the pet.

PCR testing primarily detects viral nucleic acids, leveraging the inherent advantages of the technology.Nucleic acid testing has no window period and is characterized by high specificity and high sensitivity. Its clinical concordance rate exceeds 95%.Whereas colloidal gold testing can achieve a maximum sensitivity of only 70%, thereforeNucleic acid testing is currently the gold standard for diagnosing diseases in pets.. Clinically, it is particularly suitable for infectious disease screening in newly acquired pets or those that have been exposed to animals with contagious diseases.

A number of domestic companies have already made strategic moves,Qingdao Jiditai Biotechnology Co., Ltd.(hereinafter referred to as"Ji Di Tai") is a typical representative. Recently, VCBeat conducted an interview withLiu Sen, Head of Jiditai Enterprise, which introduced us to the recent key changes in the field of nucleic acid testing for animal diseases, as well as Jiditai's product and market development strategies.

Founded in December 2020, Jiditai specializes in nucleic acid testing for pet diseases. The company has mastered core molecular diagnostic technologies and offers products such as a rapid enzyme PCR nucleic acid amplification platform, lyophilized test reagents, and PCR detection systems. Its solutions are user-friendly, enabling on-site testing, room-temperature storage, and immediate reporting.

Currently, Giditai possessesSample Release Reagent, Automated Magnetic Bead Extractor, Rapid Diagnostic Lyophilized Reagent, Rapid PCR Testing, Colorimetric Lyophilized Reagentand other products. The product portfolio is extensive and user-friendly, meeting the needs of various testing stages in veterinary medical institutions of all sizes.

Taking Jiditai’s rapid diagnostic lyophilized reagents as an example, conventional PCR reagents are supplied in liquid form and impose stringent requirements on storage temperature, environmental conditions, and cold-chain transportation. These requirements lead to issues such as instability and higher costs, thereby hindering market penetration of the products.

To address the aforementioned pain points, Jiditai has adopted rapid enzyme PCR technology, currently regarded as the “gold standard” for nucleic acid testing. This technology offers high accuracy (>98%), stable performance, and effective protection against aerosol contamination. It is capable of detecting pet diseases caused by a wide range of pathogens, including bacteria, viruses, parasites, protozoa, Chlamydia, Mycoplasma, and fungi. It is particularly suitable for diagnosing infectious diseases in dogs and cats, such as those caused by feline panleukopenia virus, feline herpesvirus, and canine/feline Mycoplasma. By overcoming the limitations of traditional testing methods (e.g., false-positive and false-negative results associated with colloidal gold strip tests), it ensures precise diagnostic outcomes.

In addition, developed by GiditaiLyophilized Microsphere TechnologySupport, enabling the detection of reagentsTransport at ambient temperature, store at room temperature, with a shelf life of up to 1 year.Facilitates the implementation of distribution models and sales promotion. Meanwhile, the product adopts pre-aliquoted single-tube reagents, ensuring individual hygiene and ease of operation.

Jiditai Rapid Diagnostic Lyophilized Reagents

When used in conjunction with Jiditai, 8-channel flow rate, temperature control accuracy ±0.1℃Rapid PCR Detection System, which can significantly reduce the detection time to 30 minutes.

Given that most veterinary clinics lack dedicated laboratory technicians, with testing tasks typically performed by veterinarians or nurses, and that space constraints in animal hospitals often preclude the establishment of specialized nucleic acid testing facilities, Kiditai has adopted a product design philosophy that prioritizes maximizing operational simplicity and minimizing product footprint, while ensuring high sensitivity and accuracy. As a result, the product is suitable for use in various types of veterinary medical institutions.

Furthermore, the team has also masteredLyophilized Microsphere Technology, Microfluidics Technology, Nucleic Acid Colorimetric Technology, Nucleic Acid Extraction Technologyand other key core technologies.

Giditan’s achievements today are inseparable from its core leadership team.

Co-founder Guan Junjie,Dr. Guan, who holds a Ph.D. from the School of Pharmaceutical Sciences at Soochow University, was recognized as an Outstanding Doctoral Graduate of Jiangsu Province and designated as a Key Shortage Talent in Suzhou’s Priority Industries. With ten years of experience in the development, regulatory registration, and manufacturing of molecular diagnostic products, Dr. Guan has successfully developed certified products spanning multiple fields, including infectious diseases, companion diagnostics, and cancer screening. Dr. Guan possesses extensive management expertise in the development of diagnostic reagent products, the management of chemical and biological pharmaceutical products, and project team leadership.

Dr. Junjie Guan

Financial Advisor Xu Bin,Head of the New Business Division at Yangtze River Pharmaceutical Group; investor in Changzhou Shanle Medical Technology Co., Ltd. and Hannin (Changzhou) Medical Technology Co., Ltd. With extensive experience in capital operations, he will assist Giditai in accelerating its industrialization.

Xu Bin

Liu Sen, Person in Charge of the Enterprise,Possesses extensive experience in product R&D, manufacturing, quality inspection, and regulatory registration; led the establishment of Quality Management Systems tailored to various stages of corporate development; demonstrates mature team management expertise.

Liu Sen

Among the remaining core team members are some of China’s earliest experts in reagent lyophilization technology, leading figures in the microfluidics industry, and team managers with a decade of experience in sales of animal diagnostic reagents. The team possesses comprehensive and complementary capabilities.

Meanwhile, Giditai has consistently accumulated R&D experience and expertise in the field of integrated equipment for PCR-based products, microfluidic products, and lyophilized products, enabling rapid product upgrades and development to meet customer needs. The company has established a technical production and quality team to support its R&D efforts, and maintains a mature and standardized quality management system to ensure efficient product commercialization.

As a veteran who has been deeply rooted in China’s pet nucleic acid testing industry since its early stages, Liu Sen offers three key insights into the future evolution of the market.

First, with the development of nucleic acid testing technology and the inherent technical advantages of nucleic acid tests themselves,Nucleic acid testing products are rapidly displacing the market for biological immunoassay products.In the coming years, a market substitution characterized by the rise of one and the fall of the other will occur between nucleic acid testing products and bio-immunology products. It is crucial for enterprises to strategically plan their R&D investments in advance.

Second, there is currently a lack of industry standards for pet nucleic acid testing products, and their promotion at this stage relies primarily on positive word-of-mouth. The establishment of industry standards will ultimately put an end to the current chaos in the sector.Products from the first batch of companies to obtain national qualifications will naturally enjoy a significant first-mover advantage in market share.Therefore, Gidita is also strategically positioning itself for relevant clinical trials to facilitate rapid regulatory approval once the regulations are enacted.

Third, amid the broader trend of all products striving to reduce usage complexity,All-in-one and handheld rapid nucleic acid testing devices will be more competitive.Meanwhile, the home healthcare setting, as a blue ocean for pet monitoring, may become a new battleground for corporate competition.

Giditai's products were launched in October last year, and within less than a year, the companyRelying on OEM serviceswithDistribution PartnershipCompletedAchieving Profitability。

In terms of the market, Giditai has alreadyBeijing, Hebei, Shandong, Jiangsu, Hunanprovinces and municipalities, etc., with500+Partnerships have been established with veterinary clinics. Moving forward, we will continue to expand our nationwide distribution network, ensuring at least one channel partner in every province and municipality.

In terms of products, Giditai is also continuously innovating and refining its offerings, with a new model expected to be launched by the end of this year.Nucleic Acid Chromogenic Products: Filling the Gap in Nucleic Acid Testing for Pet Clinics and Small-Scale Veterinary Hospitals, empowering grassroots veterinary care. Meanwhile, based on the aforementioned industry assessment, Jiditai also expects to launch in the coming one to two yearsHandheld diagnostic devices, thereby entering the broader market of home-based pet healthcare.